V Shaygannejad1,2, E Fayyazi1,3, S Badihian4, O Mirmosayyeb1,3, N Manouchehri5, F Ashtari1,2, N Asgari6. 1. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. 4. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 6. Department of Neurobiology, Institute of Molecular Medicine, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. nasgari@health.sdu.dk.
Abstract
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a B-cell-mediated disease with autoimmunity towards the astrocyte water channel aquaporin-4 (AQP-4) in the central nervous system. OBJECTIVE: To assess the long-term safety and efficacy in NMOSD patients receiving maintenance therapy with B-cell-depleting agent rituximab for more than 2 years. METHOD: NMOSD patients were included prospectively from 2014 to 2018 and received continuous cycles of rituximab infusions biannually. Incidence of adverse events (AE), serious AEs (SAE), and infusion-related AEs were evaluated through monthly phone calls and neurological examination every 4 months. RESULTS: A total of 44 NMOSD patients were included, of those 30 were treatment naive (68%). The mean age was 37.2 years with 79.5% females. With overall observation period of 31.6 ± 7.3 months (24-48 months), tolerability was assessed as satisfactory in most cases. We observed infusion reactions (mostly mild) in 31.8% of patients and 31.8% never experienced any AEs after a mean 5.1 cycles of rituximab therapy. Rituximab was also beneficial in terms of improvement in relapse rate (from 0.26 ± 0.54 to 0, P = 0.003) and Expanded Disability Status Scale (from 4.1 ± 1.8 to 3.1 ± 1.8, P < 0.001). Stratification according to AQP4-IgG serostatus showed no difference between groups. CONCLUSION: Rituximab treatment is well tolerated, safe, and efficacious with a minor risk of mild infusion reactions for NMOSD patients.
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a B-cell-mediated disease with autoimmunity towards the astrocyte water channel aquaporin-4 (AQP-4) in the central nervous system. OBJECTIVE: To assess the long-term safety and efficacy in NMOSD patients receiving maintenance therapy with B-cell-depleting agent rituximab for more than 2 years. METHOD: NMOSD patients were included prospectively from 2014 to 2018 and received continuous cycles of rituximab infusions biannually. Incidence of adverse events (AE), serious AEs (SAE), and infusion-related AEs were evaluated through monthly phone calls and neurological examination every 4 months. RESULTS: A total of 44 NMOSD patients were included, of those 30 were treatment naive (68%). The mean age was 37.2 years with 79.5% females. With overall observation period of 31.6 ± 7.3 months (24-48 months), tolerability was assessed as satisfactory in most cases. We observed infusion reactions (mostly mild) in 31.8% of patients and 31.8% never experienced any AEs after a mean 5.1 cycles of rituximab therapy. Rituximab was also beneficial in terms of improvement in relapse rate (from 0.26 ± 0.54 to 0, P = 0.003) and Expanded Disability Status Scale (from 4.1 ± 1.8 to 3.1 ± 1.8, P < 0.001). Stratification according to AQP4-IgG serostatus showed no difference between groups. CONCLUSION: Rituximab treatment is well tolerated, safe, and efficacious with a minor risk of mild infusion reactions for NMOSD patients.
Authors: D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy Journal: Blood Date: 1997-09-15 Impact factor: 22.113
Authors: H L Pellkofer; M Krumbholz; A Berthele; B Hemmer; L A Gerdes; J Havla; R Bittner; M Canis; E Meinl; R Hohlfeld; T Kuempfel Journal: Neurology Date: 2011-04-12 Impact factor: 9.910
Authors: Gurdesh S Bedi; Andrew D Brown; Sylvia R Delgado; Nida Usmani; Byron L Lam; William A Sheremata Journal: Mult Scler Date: 2011-05-26 Impact factor: 6.312
Authors: M J Fernández-Megía; B Casanova-Estruch; F Pérez-Miralles; J Ruiz-Ramos; C Alcalá-Vicente; J L Poveda-Andrés Journal: Neurologia Date: 2014-11-11 Impact factor: 3.109
Authors: Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann Journal: Brain Date: 2002-07 Impact factor: 13.501
Authors: Qiming Wang; Jeremy J Racine; Jeremy J Ratiu; Shu Wang; Rachel Ettinger; Clive Wasserfall; Mark A Atkinson; David V Serreze Journal: J Immunol Date: 2017-10-20 Impact factor: 5.422
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910
Authors: Agnieshka M Agasing; Qi Wu; Bhuwan Khatri; Nadja Borisow; Klemens Ruprecht; Alexander Ulrich Brandt; Saurabh Gawde; Gaurav Kumar; James L Quinn; Rose M Ko; Yang Mao-Draayer; Christopher J Lessard; Friedemann Paul; Robert C Axtell Journal: Nat Commun Date: 2020-06-05 Impact factor: 14.919